Jade Biosciences, Inc. (JBIO)
NCM · Healthcare · Biotechnology
$15.34
-4.60%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$933.6M
Shares Outstanding
60.9M
Exchange
NCM
Currency
USD
About Jade Biosciences, Inc.
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -27.8M | -27.4M | -35.0M | -43.4M |
| Net Income | -32.1M | -25.2M | -31.9M | -40.4M |
| Diluted EPS | $-0.86 | $-0.48 | $nan | $-0.57 |
Annual Financials
| Metric | 2025-12-31 |
|---|---|
| Revenue | 0.00 |
| Operating Income | -113.5M |
| Net Income | -127.4M |
| Diluted EPS | $-3.19 |